CSTONE PHARMA-B (02616) saw its shares rise more than 4% again. At the time of writing, the stock was up 3.77% to HK$7.14, with a turnover of HK$35.6465 million. The movement follows an announcement on March 25 that the company's core commercial product, sugemalimab, received a [I, A] grade recommendation in the European Society for Medical Oncology (ESMO) guidelines. Specifically, sugemalimab has been included in the "Early and Locally Advanced Non-Small-Cell Lung Cancer Living Guideline" for use as consolidation therapy in patients with stage III non-small cell lung cancer (NSCLC) following concurrent or sequential chemoradiotherapy. This recommendation is expected to significantly facilitate sugemalimab's market access processes in the European Union and other regions, benefiting a broader patient population and providing strong support for its global commercial expansion. In February 2025, the combination of sugemalimab and chemotherapy had already received a [I, A] recommendation from the ESMO "Metastatic Non-Small-Cell Lung Cancer Living Guideline" for the first-line treatment of both squamous and non-squamous stage IV NSCLC. With this latest inclusion, both lung cancer indications for which sugemalimab is approved in the EU and UK are now covered by ESMO guidelines, underscoring its clinical value. To date, CSTONE PHARMA-B has established four commercial partnerships for sugemalimab in Europe, the Middle East, Africa, and Latin America, extending its commercial network to over 60 countries and regions worldwide. Market access applications for the drug have been approved or are under review in more than ten countries, indicating steady and efficient progress in its overseas commercialization strategy.
Comments